PARMODIA Trademark

Trademark Overview


On Friday, February 17, 2023, a trademark application was filed for PARMODIA with the United States Patent and Trademark Office. The USPTO has given the PARMODIA trademark a serial number of 79370102. The federal status of this trademark filing is REGISTERED as of Tuesday, February 6, 2024. This trademark is owned by KOWA COMPANY, LTD.. The PARMODIA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of diseases of the circulatory system and diabetes-related diseases, pharmaceutical preparations for treatment of fatty liver and steatohepatitis, pharmaceutical preparations for the treatment of cardiovascular disorders and metabolic disorders, pharmaceutical preparations for the treatment of digestive system disease, pharmaceutical preparations for the treatment of primary biliary cirrhosis, pharmaceutical preparations for the treatment of fatty liver and liver hepatitis and liver cirrhosis, pharmaceutical preparations for the treatment of liver disease, pharmaceutical preparations for the treatment of metabolic disease, pharmaceutical preparations for the prevention and treatment of disorders of the metabolic system, analgesics; pharmaceutical and biological preparations for the treatment of diseases of the central nervous system, peripheral nervous system, sensory organs, the circulatory system, resp...
parmodia

General Information


Serial Number79370102
Word MarkPARMODIA
Filing DateFriday, February 17, 2023
Status700 - REGISTERED
Status DateTuesday, February 6, 2024
Registration Number7296358
Registration DateTuesday, February 6, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 21, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of diseases of the circulatory system and diabetes-related diseases, pharmaceutical preparations for treatment of fatty liver and steatohepatitis, pharmaceutical preparations for the treatment of cardiovascular disorders and metabolic disorders, pharmaceutical preparations for the treatment of digestive system disease, pharmaceutical preparations for the treatment of primary biliary cirrhosis, pharmaceutical preparations for the treatment of fatty liver and liver hepatitis and liver cirrhosis, pharmaceutical preparations for the treatment of liver disease, pharmaceutical preparations for the treatment of metabolic disease, pharmaceutical preparations for the prevention and treatment of disorders of the metabolic system, analgesics; pharmaceutical and biological preparations for the treatment of diseases of the central nervous system, peripheral nervous system, sensory organs, the circulatory system, respiratory system, and the digestive system; pharmaceutical substances for the treatment of dermatological diseases, allergies and urogenital or anal conditions; veterinary preparations, namely, veterinary preparations for the treatment of diseases of the circulatory system and diabetes-related diseases, veterinary preparations for treatment of fatty liver and steatohepatitis, veterinary preparations for the treatment of cardiovascular disorders and metabolic disorders, veterinary preparations for the treatment of digestive system disease, veterinary preparations for the treatment of primary biliary cirrhosis, veterinary preparations for the treatment of fatty liver and liver hepatitis and liver cirrhosis, veterinary preparations for the treatment of liver disease, veterinary preparations for the treatment of metabolic disease, veterinary preparations for the prevention and treatment of disorders of the metabolic system, analgesics; veterinary pharmaceutical and biological preparations for the treatment of diseases of the central nervous system, peripheral nervous system, sensory organs, the circulatory system, respiratory system, and the digestive system; veterinary pharmaceutical substances for the treatment of dermatological diseases, allergies and urogenital or anal conditions; sanitary preparations for medical use; anti-inflammatory agents, namely, topical preparations in the form of gels and salves, adhesive skin patches, liquid formulations, cream and sprays, all for relieving pain

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, May 19, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameKOWA COMPANY, LTD.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressJP

Party NameKOWA COMPANY, LTD.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressJP

Party NameKOWA COMPANY, LTD.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressJP

Trademark Events


Event DateEvent Description
Thursday, May 18, 2023SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Friday, May 19, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, May 23, 2023APPLICATION FILING RECEIPT MAILED
Thursday, May 25, 2023ASSIGNED TO EXAMINER
Wednesday, June 7, 2023NON-FINAL ACTION WRITTEN
Thursday, June 8, 2023NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, July 12, 2023CORRECTION TRANSACTION RECEIVED FROM IB
Friday, July 14, 2023REFUSAL PROCESSED BY MPU
Friday, July 14, 2023NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Monday, July 24, 2023CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED
Monday, July 24, 2023INTERNATIONAL REGISTRATION RENEWED
Monday, August 14, 2023REFUSAL PROCESSED BY IB
Saturday, September 2, 2023ATTORNEY REVIEW COMPLETED
Tuesday, October 3, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, October 3, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, October 3, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, October 13, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 1, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, November 1, 2023NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, November 1, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Tuesday, November 21, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 21, 2023PUBLISHED FOR OPPOSITION
Monday, November 27, 2023NOTIFICATION PROCESSED BY IB
Tuesday, February 6, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, February 6, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Monday, May 6, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Monday, June 17, 2024FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, May 13, 2024FINAL DISPOSITION PROCESSED
Monday, May 13, 2024FINAL DISPOSITION NOTICE SENT TO IB